Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

Background Exenatide (exendin‐4) exhibits dose‐dependent glucoregulatory activity, but causes dose‐limiting nausea and vomiting. This study was designed to formally assess the possibility of inducing tolerance to the side effects of nausea and vomiting at therapeutic doses of exenatide, using a dose...

Full description

Saved in:

Bibliographic Details
Published in:	Diabetes/metabolism research and reviews Vol. 20; no. 5; pp. 411 - 417
Main Authors:	Fineman, Mark S., Shen, Larry Z., Taylor, Kristin, Kim, Dennis D., Baron, Alain D.
Format:	Journal Article
Language:	English
Published:	Chichester, UK John Wiley & Sons, Ltd 01.09.2004 Wiley
Subjects:	Adolescent Adult Aged Biological and medical sciences Blood Glucose - metabolism Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance dose-escalation Endocrine pancreas. Apud cells (diseases) Endocrinopathies exenatide exendin-4 Female Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects incretin mimetic Male Medical sciences Middle Aged mitigation of side effects Nausea - chemically induced Nausea - prevention & control Peptides - administration & dosage Peptides - adverse effects reduction of adverse events type 2 diabetes Venoms - administration & dosage Venoms - adverse effects Endocrinopathy Type 2 diabetes Human incretin mimetic Mimetic dose- escalation Exenatide reduction of adverse events Increasing dose Hypoglycemic agent Secondary effect mitigation of side effects exendin-4
ISSN:	1520-7552, 1520-7560
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!